What's Going On With Eli Lilly Stock Today?
Portfolio Pulse from Vandana Singh
Eli Lilly (NYSE:LLY) is preparing to announce its Q4 2023 financial results on February 6, with analysts expecting earnings of $2.19 per share and sales of $8.932 billion. Despite recent FDA scrutiny over manufacturing issues at its New Jersey plant, the company maintains a positive outlook with plans to expand its weight-loss drug Mounjaro. Cantor Fitzgerald reaffirmed an Overweight rating with a $630 price target. Shares rose 1.32% to $669.14.
February 02, 2024 | 5:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly is anticipated to announce strong Q4 2023 results, maintains positive growth with Mounjaro expansion despite FDA scrutiny. Shares are currently up, reflecting investor confidence.
The anticipation of strong Q4 results combined with strategic expansion plans for Mounjaro, despite recent regulatory challenges, suggests a positive short-term impact on LLY's stock. The reaffirmation of an Overweight rating by Cantor Fitzgerald and the recent price action further support this outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100